Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressives

The primary objectives are to systematically review the prevalence of immunogenicity to biologics with the use of different test assays, the impact of ADA formation on the efficacy and safety of biologics and the influence of combination therapy on immunogenicity in patients with IBD.

This is a protocol.